RAPID-COVID

Robust automation and point of care identification of COVID

Summary

While the world focuses on COVID-19, other infectious diseases with similar symptoms continue to circulate. In fact, around 5 % of people with COVID-19 and 18 % of non-COVID patients have other infections. Rapidly identifying and diagnosing not only COVID-19, but other infections such as colds and the flu, will ensure that COVID-19 patients can be quickly isolated, limiting the spread of the disease. Furthermore, rapid diagnosis of infections besides COVID-19 will ensure that all patients receive the right treatments, and reduce the unnecessary use of antibiotics.

The aim of RAPID-COVID is to develop a diagnostic kit capable of simultaneously detecting SARS-CoV-2 (the virus that causes COVID-19) plus 30 other common respiratory bacteria and viruses. The consortium already has a prototype technology called MPA (Multiplex Probe Amplification), and the goal of the project is to validate this and get a CE mark for both point of care (PoC) and high throughput laboratory testing.

A number of elements set the RAPID-COVID system apart from other tests. Firstly, the tests are run on one tube, instead of multiple tubes. Secondly, it is automated, meaning users can quickly process a large number of patient samples. Finally, its compact size means it does not take up a lot of space in the lab.

The project partners aim to commercialise the test for EUR 9 per test. Ultimately, they hope it will allow for accurate, cost-effective and comprehensive diagnoses during the current outbreak as well as future routine diagnosis

Participants

  Show participants on map
Universities, research organisations, public bodies, non-profit groups
  • Agencia Publica Empresarial Sanitaria Costa Del Sol, Marbella Malaga, Spain
  • Assistance Publique Hopitaux De Paris, Paris, France
Small and medium-sized enterprises (SMEs) and mid-sized companies (<€500 m turnover)
  • Biosistemika, Raziskave In Razvoj Doo, Ljubljana, Slovenia
  • Genefirst Limited, Abingdon, United Kingdom
  • Primadiag SAS, Romainville, France

Participants
NameIHI funding in €
Agencia Publica Empresarial Sanitaria Costa Del Sol311 250
Assistance Publique Hopitaux De Paris543 813
Biosistemika, Raziskave In Razvoj Doo314 375
Genefirst Limited1 005 688
Primadiag SAS657 460
Total Cost2 832 586